Hombrouck Anneleen, De Rijck Jan, Hendrix Jelle, Vandekerckhove Linos, Voet Arnout, De Maeyer Marc, Witvrouw Myriam, Engelborghs Yves, Christ Frauke, Gijsbers Rik, Debyser Zeger
The Laboratory for Molecular Virology and Gene Therapy, KULeuven and IRC KULAK, Leuven, Flanders, Belgium.
PLoS Pathog. 2007 Mar;3(3):e47. doi: 10.1371/journal.ppat.0030047.
Retroviruses by definition insert their viral genome into the host cell chromosome. Although the key player of retroviral integration is viral integrase, a role for cellular cofactors has been proposed. Lentiviral integrases use the cellular protein LEDGF/p75 to tether the preintegration complex to the chromosome, although the existence of alternative host proteins substituting for the function of LEDGF/p75 in integration has been proposed. Truncation mutants of LEDGF/p75 lacking the chromosome attachment site strongly inhibit HIV replication by competition for the interaction with integrase. In an attempt to select HIV strains that can overcome the inhibition, we now have used T-cell lines that stably express a C-terminal fragment of LEDGF/p75. Despite resistance development, the affinity of integrase for LEDGF/p75 is reduced and replication kinetics in human primary T cells is impaired. Detection of the integrase mutations A128T and E170G at key positions in the LEDGF/p75-integrase interface provides in vivo evidence for previously reported crystallographic data. Moreover, the complementary inhibition by LEDGF/p75 knockdown and mutagenesis at the integrase-LEDGF/p75 interface points to the incapability of HIV to circumvent LEDGF/p75 function during proviral integration. Altogether, the data provide a striking example of the power of viral molecular evolution. The results underline the importance of the LEDGF/p75 HIV-1 interplay as target for innovative antiviral therapy. Moreover, the role of LEDGF/p75 in targeting integration will stimulate research on strategies to direct gene therapy vectors into safe landing sites.
根据定义,逆转录病毒会将其病毒基因组插入宿主细胞染色体。尽管逆转录病毒整合的关键因子是病毒整合酶,但已有研究提出细胞辅助因子也发挥作用。慢病毒整合酶利用细胞蛋白LEDGF/p75将整合前复合物 tether 到染色体上,不过也有人提出存在替代LEDGF/p75在整合中功能的其他宿主蛋白。缺乏染色体附着位点的LEDGF/p75截短突变体通过竞争与整合酶的相互作用,强烈抑制HIV复制。为了筛选出能克服这种抑制作用的HIV毒株,我们现在使用了稳定表达LEDGF/p75 C端片段的T细胞系。尽管产生了抗性,但整合酶对LEDGF/p75的亲和力降低,且在人原代T细胞中的复制动力学受到损害。在LEDGF/p75 - 整合酶界面关键位置检测到整合酶突变A128T和E170G,为先前报道的晶体学数据提供了体内证据。此外,在整合酶 - LEDGF/p75界面处,LEDGF/p75敲低和诱变的互补抑制作用表明,HIV在原病毒整合过程中无法规避LEDGF/p75的功能。总体而言,这些数据为病毒分子进化的力量提供了一个显著例子。结果强调了LEDGF/p75与HIV - 1相互作用作为创新抗病毒治疗靶点的重要性。此外,LEDGF/p75在靶向整合中的作用将刺激关于将基因治疗载体引导至安全着陆位点策略的研究。